Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts
Portfolio Pulse from Benzinga Insights
Over the past three months, 8 analysts have shared their insights on Gilead Sciences (NASDAQ:GILD), with opinions ranging from bullish to bearish. The average 12-month price target has increased to $77.25 from $74.86. Key analysts have adjusted their ratings and price targets, reflecting their responses to recent developments. Gilead Sciences shows strong financial metrics, including a net margin of 23.21% and a return on equity of 9.01%.
August 15, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have mixed views on Gilead Sciences, with an average 12-month price target of $77.25, up from $74.86. Financial metrics such as net margin and ROE are strong, indicating effective cost control and utilization of equity capital.
The increase in the average price target and strong financial metrics suggest a positive outlook for Gilead Sciences. Analysts' mixed views indicate some uncertainty, but the overall sentiment leans towards a slight positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100